JP2015504082A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504082A5
JP2015504082A5 JP2014552660A JP2014552660A JP2015504082A5 JP 2015504082 A5 JP2015504082 A5 JP 2015504082A5 JP 2014552660 A JP2014552660 A JP 2014552660A JP 2014552660 A JP2014552660 A JP 2014552660A JP 2015504082 A5 JP2015504082 A5 JP 2015504082A5
Authority
JP
Japan
Prior art keywords
composition
protein
composition according
polypeptide
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504082A (ja
JP6084987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/051163 external-priority patent/WO2013110621A1/en
Publication of JP2015504082A publication Critical patent/JP2015504082A/ja
Publication of JP2015504082A5 publication Critical patent/JP2015504082A5/ja
Application granted granted Critical
Publication of JP6084987B2 publication Critical patent/JP6084987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552660A 2012-01-23 2013-01-22 セミフッ素化アルカンに基づく安定化タンパク質組成物 Active JP6084987B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152159 2012-01-23
EP12152159.5 2012-01-23
PCT/EP2013/051163 WO2013110621A1 (en) 2012-01-23 2013-01-22 Stabilised protein compositions based on semifluorinated alkanes

Publications (3)

Publication Number Publication Date
JP2015504082A JP2015504082A (ja) 2015-02-05
JP2015504082A5 true JP2015504082A5 (enExample) 2016-02-18
JP6084987B2 JP6084987B2 (ja) 2017-02-22

Family

ID=47598843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552660A Active JP6084987B2 (ja) 2012-01-23 2013-01-22 セミフッ素化アルカンに基づく安定化タンパク質組成物

Country Status (14)

Country Link
US (2) US9757460B2 (enExample)
EP (1) EP2806886B1 (enExample)
JP (1) JP6084987B2 (enExample)
KR (1) KR101989648B1 (enExample)
CN (1) CN104066442B (enExample)
AU (1) AU2013211645B2 (enExample)
BR (1) BR112014017719A8 (enExample)
CA (1) CA2862974C (enExample)
DK (1) DK2806886T3 (enExample)
ES (1) ES2625538T3 (enExample)
MX (1) MX361681B (enExample)
PL (1) PL2806886T3 (enExample)
PT (1) PT2806886T (enExample)
WO (1) WO2013110621A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN114028560A (zh) * 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
AU2015227307A1 (en) * 2014-03-03 2016-10-13 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) * 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
JP7761562B2 (ja) * 2019-11-27 2025-10-28 ノバリック ゲーエムベーハー 非水性溶媒で懸濁されたタンパク質粒子を含む懸濁製剤
CN115487305A (zh) * 2022-09-21 2022-12-20 江苏君隽生物科技有限公司 一种用于递送活性药物成分的液体组合物
WO2025133214A1 (en) 2023-12-21 2025-06-26 Novaliq Gmbh Ophthalmic polypeptide compositions for the treatment of posterior eye disorders

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
BR9904780A (pt) 1998-02-09 2000-03-08 Macrochem Corp Esmalte fungicida para unhas e método de uso do mesmo
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
KR20080045300A (ko) 1999-02-08 2008-05-22 알자 코포레이션 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
DE60223694T2 (de) 2001-09-04 2008-10-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
EP1507513A1 (de) 2002-05-24 2005-02-23 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1639018A1 (en) 2003-06-20 2006-03-29 Noveon IP Holdings Corp. Galactomannan hydrocolloids
CA2536482C (en) 2003-08-25 2012-07-24 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
CA2540621A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
ES2387619T3 (es) 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
EP1922060B1 (en) 2005-08-05 2009-01-14 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス,インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
EP2110126B9 (de) * 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス,インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) * 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2010150378A1 (ja) 2009-06-25 2010-12-29 ライオン株式会社 眼科用組成物
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
EP2387391B1 (de) 2009-07-24 2017-01-11 MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH Verfahren zur entwicklung einer als schaum auf die haut zu applizierenden flüssigen zusammensetzung sowie eine topisch applizierbare zusammensetzung
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CA2792517C (en) 2010-03-09 2020-03-24 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
KR101910213B1 (ko) 2011-01-04 2018-12-19 노바리크 게엠베하 부분불소화된 알칸을 포함하는 수중유형 에멀젼
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物

Similar Documents

Publication Publication Date Title
Villemagne et al. Tuberculosis: the drug development pipeline at a glance
HRP20211053T1 (hr) Modificirani fgf-21 polipeptidi i njihove primjene
Samson et al. Influenza virus resistance to neuraminidase inhibitors
JP2012041342A5 (enExample)
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
JP2017537612A5 (enExample)
HK1220116A1 (zh) 使用纯化的两亲性多肽组合物的外科手术方法
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2014526441A5 (enExample)
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
JP2013501816A5 (enExample)
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
BR112013019744A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
JP2014501121A5 (enExample)
EP3575314A3 (en) Glucagon derivatives
RU2015134583A (ru) Фармацевтические композиции, содержащие доноры нитроксила
JP2013544842A5 (enExample)
EP4613284A3 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
EA201791147A1 (ru) Фармацевтическая композиция, ее получение и применения
JP2014515407A5 (enExample)
JP2020514305A5 (enExample)
BR112015003733A2 (pt) composições de liberação estendida de um nitrato de aminoalquila